Crescita Therapeutics Reports Q1 2026 Financial Results and Updates ClinActiv Acquisition Status
Crescita Therapeutics Inc., a Canadian commercial dermatology company, announced its financial results for the first quarter ended March 31, 2026. The company reported revenue of $5.637 million CAD, representing a significant increase from $3.537 million in the same period last year. Gross profit rose to $2.644 million, while Adjusted EBITDA improved markedly to $238,000 compared to a loss in the previous year. Despite higher operating expenses, the net loss remained manageable at $1.16 million. CEO Serge Verreault attributed the growth to increased manufacturing volumes and revenue from recently acquired skincare assets. Concurrently, Crescita provided updates on its proposed all-cash acquisition by ClinActiv Holdings Inc. at $0.80 per share. The company has filed materials for a special shareholder meeting scheduled for May 14, 2026, to approve the arrangement. An interim court order has been obtained to proceed with the voting process. Subject to shareholder and final court approval, the transaction is expected to close in the second quarter of 2026, resulting in the delisting of Crescita’s shares from the Toronto Stock Exchange.
Wire timeline
Crescita Therapeutics Reports Q1 2026 Financial Results and Updates ClinActiv Acquisition Status
Crescita Therapeutics Inc., a Canadian commercial dermatology company, announced its financial results for the first quarter ended March 31, 2026. The company reported revenue of $5.637 million CAD, representing a significant increase from $3.537 million in the same period last year. Gross profit rose to $2.644 million, while Adjusted EBITDA improved markedly to $238,000 compared to a loss in the previous year. Despite higher operating expenses, the net loss remained manageable at $1.16 million. CEO Serge Verreault attributed the growth to increased manufacturing volumes and revenue from recently acquired skincare assets. Concurrently, Crescita provided updates on its proposed all-cash acquisition by ClinActiv Holdings Inc. at $0.80 per share. The company has filed materials for a special shareholder meeting scheduled for May 14, 2026, to approve the arrangement. An interim court order has been obtained to proceed with the voting process. Subject to shareholder and final court approval, the transaction is expected to close in the second quarter of 2026, resulting in the delisting of Crescita’s shares from the Toronto Stock Exchange.
Financial Post